Hamaya, Tomoko
Hatakeyama, Shingo http://orcid.org/0000-0002-0026-4079
Yoneyama, Tohru
Tobisawa, Yuki
Kodama, Hirotake
Fujita, Takeshi
Murakami, Reiichi
Fujita, Naoki
Okamoto, Teppei
Yamamoto, Hayato
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Saitoh, Hisao
Narumi, Shunji
Tomita, Hirofumi
Ohyama, Chikara
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K09517, 21K09339, 19H05556)
Article History
Received: 28 November 2021
Accepted: 11 March 2022
First Online: 7 April 2022
Competing interests
: Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K. and Pfizer Inc. and supported by a grant from NIPRO Corporation. Chikara Ohyama received honoraria from Astellas Pharma Inc., NIPPON SHINYAKU Company Ltd., AstraZeneca K.K., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Ltd., Novartis Pharma K.K., ONO Pharmaceutical Company Ltd., Chugai Pharmaceutical Company Ltd., Sanofi S.A., Bayer AG., Pfizer Inc., Bristol Myers Squibb, Otsuka Pharmaceutical Company Ltd., KISSEI Pharmaceutical Company Ltd., Kyowa Kirin Company Ltd., Daiichi Sankyo Company Ltd., KANEKA Corporation, and Nipro Corporation. The other authors have no potential conflicts of interest to disclose.